恩扎卢胺联合雄激素剥夺治疗转移性激素敏感性前列腺癌的八年结局
ENZAMET研究8.1年随访显示,恩扎卢胺联合睾酮抑制相比第一代非甾体抗雄激素显著延长转移性激素敏感性前列腺癌患者总生存(中位7.9 vs 5.8年,HR 0.73,95%CI 0.63-0.86,P=0.0001),8年总生存率50% vs 40%,且未增加非前列腺癌死亡率,但跌倒发生率更高。
要点
- 恩扎卢胺组8年临床无进展生存率43% vs 20%(HR 0.49,95%CI 0.42-0.57)。
- 两组心脏和神经系统3-5级不良事件率相似,恩扎卢胺组跌倒更多(0.70 vs 0.24/100人年)。
核心结论
- 恩扎卢胺联合睾酮抑制在8年时持续提供显著总生存获益,且不增加非前列腺癌死亡率。
研究设计与样本
- 随机对照试验,转移性激素敏感性前列腺癌患者1:1随机接受恩扎卢胺或第一代非甾体抗雄激素联合睾酮抑制,允许同期早期多西他赛。
- 恩扎卢胺组563例,非甾体抗雄激素组562例,中位随访8.1年(97个月)。
主要发现
- 恩扎卢胺组死亡285/563(51%),非甾体抗雄激素组337/562(60%)。
- 中位总生存7.9 vs 5.8年,8年总生存率50% vs 40%,HR 0.73(95%CI 0.63-0.86),P=0.0001。
- 8年临床无进展生存率43% vs 20%,HR 0.49(95%CI 0.42-0.57),P<0.0001。
- 622例死亡中468例归因于前列腺癌(恩扎卢胺组207例 vs 非甾体抗雄激素组261例),其他原因死亡两组相似(78 vs 76)。
- 恩扎卢胺组中位治疗持续时间4.8年,非甾体抗雄激素组1.9年;数据截止时185例(33%)仍在接受恩扎卢胺,其中163例(88%)维持160mg全剂量。
关键数值与推荐
- 心脏疾病3-5级不良事件每100人年发生率:恩扎卢胺组2.2 vs 非甾体抗雄激素组2.2。
- 神经系统疾病3-5级不良事件每100人年发生率:恩扎卢胺组2.3 vs 非甾体抗雄激素组2.0。
- 跌倒每100人年发生率:恩扎卢胺组0.70 vs 非甾体抗雄激素组0.24。
临床怎么用
- 对于转移性激素敏感性前列腺癌,恩扎卢胺联合睾酮抑制可作为长期治疗选择,需关注跌倒风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We previously reported that, at median follow-ups of 34 and 68 months, enzalutamide improved overall survival (OS) compared with a first-generation nonsteroidal antiandrogen (NSAA) when used with testosterone suppression for metastatic hormone-sensitive prostate cancer (mHSPC). We now report longer-term outcomes with a focus on adverse events (AEs) and causes of death. PATIENTS AND METHODS: Participants with mHSPC were randomly assigned (1 : 1) to receive daily enzalutamide or NSAA in addition to testosterone suppression; concurrent early docetaxel was permitted at clinician discretion. OS was the primary endpoint; secondary endpoints included progression-free survival (PFS), cause-specific survival, duration of treatment, and AEs. RESULTS: At a median follow-up of 8.1 years (97 months), deaths occurred in 285 of 563 (51%) participants assigned enzalutamide versus 337 of 562 (60%) assigned NSAA. OS was longer with enzalutamide than with NSAA [median 7.9 versus 5.8 years; OS at 8 years 50% versus 40%; hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.63-0.86, P = 0.0001]. Clinical PFS at 8 years also favoured enzalutamide (43% versus 20%; HR 0.49, 95% CI 0.42-0.57, P < 0.0001). Of the 622 deaths, 468 were attributed to prostate cancer, of which fewer were associated with enzalutamide than with NSAA (207 versus 261), whereas deaths attributed to other causes occurred with similar frequency in the two groups (78 versus 76). Median treatment duration was 4.8 years with enzalutamide and 1.9 years with NSAA. Of 185 of 563 (33%) participants still receiving enzalutamide at data cut-off, most (163 of 185, 88%) remain on the full 160-mg dose. Rates of grade 3-5 AEs per 100 person-years were similar between groups for cardiac (2.2 versus 2.2) and nervous system disorders (2.3 versus 2.0), with more falls observed with enzalutamide (0.70 versus 0.24). CONCLUSION: Enzalutamide continues to provide substantial long-term OS benefit at 8 years, with sustained efficacy, maintenance of full dose in most participants, and no increase in non-prostate cancer mortality.
引用
- Zhang AY, Thomas H, Begbie S, et al. Eight-year outcomes of testosterone suppression plus enzalutamide or a nonsteroidal antiandrogen for metastatic hormone-sensitive prostate cancer (ENZAMET; ANZUP 1304). Ann Oncol. 2026. PMID: 42607762. doi:10.1016/j.annonc.2026.07.412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。